Paper40355804
Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma.
Shimizu T and 5 others. Cancer Sci, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma. Papers, record 40355804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40355804
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| YY1 Transcription Factor | Major topic |
| Leukemia-Lymphoma, Adult T-Cell | Major topic |
| Enhancer of Zeste Homolog 2 Protein | Major topic |
| MutL Protein Homolog 1 | Major topic |
| Humans | |
| Up-Regulation | |
| Gene Expression Regulation, Neoplastic | |
| Cell Line, Tumor | |
| Epigenesis, Genetic | |
| Cell Proliferation |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| JP19K08812 | Japan Society for the Promotion of Science | PubMed | ||
| JP23K07811 | Japan Society for the Promotion of Science | PubMed | ||
| Grant-in-aid | Uehara Memorial Foundation | PubMed | ||
| JP21ek0510035h0001-0003 | Japan Agency for Medical Research and Development | PubMed |
Source PubMed
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1751370 | Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). | Br J Haematol | 1991 | https://conductscience.org/library/papers/1751370 | PubMed |
| 2 | 33075812 | How I treat adult T-cell leukemia/lymphoma. | Blood | 2021 | https://conductscience.org/library/papers/33075812 | PubMed |
| 3 | 25847015 | T memory stem cells are the hierarchical apex of adult T-cell leukemia. | Blood | 2015 | https://conductscience.org/library/papers/25847015 | PubMed |
| 4 | 28515095 | Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/28515095 | PubMed |
| 5 | 30428369 | YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells. | iScience | 2018 | https://conductscience.org/library/papers/30428369 | PubMed |
| 6 | 38383791 | Mechanisms of action and resistance in histone methylation-targeted therapy. | Nature | 2024 | https://conductscience.org/library/papers/38383791 | PubMed |
| 7 | 26361794 | Treatment and survival among 1594 patients with ATL. | Blood | 2015 | https://conductscience.org/library/papers/26361794 | PubMed |
| 8 | 40355804 | Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40355804 | PubMed |
| 9 | 34433624 | KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia. | Immunohorizons | 2021 | https://conductscience.org/library/papers/34433624 | PubMed |
| 10 | 28596308 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Science | 2017 | https://conductscience.org/library/papers/28596308 | PubMed |
| 11 | 35030628 | Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. | Blood Adv | 2022 | https://conductscience.org/library/papers/35030628 | PubMed |
| 12 | 30057145 | Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. | Cancer Cell | 2018 | https://conductscience.org/library/papers/30057145 | PubMed |
| 13 | 28522752 | Mismatch Repair Proteins Initiate Epigenetic Alterations during Inflammation-Driven Tumorigenesis. | Cancer Res | 2017 | https://conductscience.org/library/papers/28522752 | PubMed |
| 14 | 21228036 | Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. | Haematologica | 2011 | https://conductscience.org/library/papers/21228036 | PubMed |
| 15 | 26601161 | Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia. | Sci Adv | 2015 | https://conductscience.org/library/papers/26601161 | PubMed |
| 16 | 26028255 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26028255 | PubMed |
| 17 | 15944788 | Methylation of the MLH1 gene in hematological malignancies. | Oncol Rep | 2005 | https://conductscience.org/library/papers/15944788 | PubMed |
| 18 | 29186113 | Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. | Nature | 2017 | https://conductscience.org/library/papers/29186113 | PubMed |
| 19 | 24727323 | CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24727323 | PubMed |
| 20 | 8437212 | Proliferative response of Tax1-transduced primary human T cells to anti-CD3 antibody stimulation by an interleukin-2-independent pathway. | J Virol | 1993 | https://conductscience.org/library/papers/8437212 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42095244 | SWI/SNF alterations define a subgroup with poorer outcome among patients with aggressive forms of adult T-cell leukemia/lymphoma. | Haematologica | 2026 | https://conductscience.org/library/papers/42095244 | PubMed |
| 40867514 | Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy. | Biomolecules | 2025 | https://conductscience.org/library/papers/40867514 | PubMed |
| 40355804 | Upregulation of YY1/EZH2 and MLH1 as Therapeutic Targets for Adult T-Cell Leukemia/Lymphoma. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40355804 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CADM1 | 23705 | PubTator's text mining | https://conductscience.org/library/genes/23705 | NCBI Gene |
| CCR4 | 1233 | PubTator's text mining | https://conductscience.org/library/genes/1233 | NCBI Gene |
| CD48 | 962 | PubTator's text mining | https://conductscience.org/library/genes/962 | NCBI Gene |
| EZH2 | 2146 | PubTator's text mining | https://conductscience.org/library/genes/2146 | NCBI Gene |
| MSH2 | 4436 | PubTator's text mining | https://conductscience.org/library/genes/4436 | NCBI Gene |
| YY1 | 7528 | PubTator's text mining | https://conductscience.org/library/genes/7528 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40355804
GET https://conductscience.org/api/papers/v1/40355804/references?page=2